Ambeed.cn

首页 / / / Akt / Miransertib HCl

Miransertib HCl {[allProObj[0].p_purity_real_show]}

货号:A803512

Miransertib HCl是一种全能型 Akt 抑制剂,对 Akt1、Akt2 和 Akt3 的 IC50 值分别为 2.7 nM、14 nM和8.1 nM。其作用机制是通过阻断 Akt 的膜转位,抑制其从无活性形式转移到膜上,并且能够去磷酸化膜相关的活性形式。

Miransertib HCl 化学结构 CAS号:1313883-00-9
Miransertib HCl 化学结构
CAS号:1313883-00-9
Miransertib HCl 3D分子结构
CAS号:1313883-00-9
Miransertib HCl 化学结构 CAS号:1313883-00-9
Miransertib HCl 3D分子结构 CAS号:1313883-00-9
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Miransertib HCl 纯度/质量文件 产品仅供科研

货号:A803512 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nature,2025. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
Cell,2025. Ambeed. [ A122167 ]
Science,2025,387(6729):eadp5637. Ambeed. [ A875019 ]
Sig. Transduct. Target. Ther.,2025,10,257. Ambeed. [ A104916 ]
Nat. Mater.,2025,24,1116-1125. Ambeed. [ A141030 , A131652 ]
更多 >
产品名称 Akt Akt1 Akt2 Akt3 其他靶点 纯度
Honokiol MEK 98%
PF-04691502 ++++

P-Akt (S473), IC50: 3.8 nM

P-Akt (T308), IC50: 7.5 nM

98+%
PHT-427 +

Akt, Ki: 2.7 μM

99%+
Deguelin PI3K 99%+
TIC10 isomer ERK 98+%
Perifosine +

Akt, IC50: 4.7 μM

98%
Miltefosine PKC,PI3K 98%
Triciribine +

Akt, IC50: 130 nM

99%+
Uprosertib +

Akt1, IC50: 180 nM

+

Akt2, IC50: 328 nM

++

Akt3, IC50: 38 nM

99%+
Afuresertib ++++

Akt1, Ki: 0.08 nM

++++

Akt2, Ki: 2 nM

++++

Akt3, Ki: 2.6 nM

99%+
Miransertib ++++

Akt1, IC50: 5 nM

++++

Akt2, IC50: 4.5 nM

++

Akt3, IC50: 16 nM

98+%
GSK-690693 ++++

Akt1, IC50: 2 nM

+++

Akt2, IC50: 13 nM

+++

Akt3, IC50: 9 nM

99%+
AT7867 ++

Akt1, IC50: 32 nM

++

Akt2, IC50: 17 nM

++

Akt3, IC50: 47 nM

PKA 99%+
AKT inhibitor VIII ++

Akt1, IC50: 58 nM

+

Akt2, IC50: 210 nM

+

Akt3, IC50: 2119 nM

97%
MK-2206 2HCl +++

Akt1, IC50: 8 nM

+++

Akt2, IC50: 12 nM

+

Akt3, IC50: 65 nM

99%+
Ipatasertib ++++

Akt1, IC50: 5 nM

++

Akt2, IC50: 18 nM

+++

Akt3, IC50: 8 nM

99%+
AT13148 ++

Akt1, IC50: 38 nM

+

Akt2, IC50: 402 nM

++

Akt3, IC50: 50 nM

PKA 95%
Capivasertib ++++

Akt1, IC50: 3 nM

+++

Akt2, IC50: 8 nM

+++

Akt3, IC50: 8 nM

99%+
A-674563 HCl +++

Akt1, Ki: 11 nM

PKA 99%
CCT128930 +++

Akt2, IC50: 6 nM

PKA 95%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Miransertib HCl 生物活性

描述 The AGC kinases AKT1, AKT2, and AKT3 are key mediators of the PI3K/AKT/mTOR signaling pathway, which promotes diverse physiological processes such as proliferation, migration, antiapoptotic survival, and protein synthesis. Allosteric inhibitors offer a unique advantage over ATP-competitive inhibitors in that very high kinase selectivity can be achieved by targeting a distinct allosteric pocket in AKT formed by the pleckstrin homology (PH) and kinase domains. Miransertib (ARQ 092) is an investigational orally available potent and selective allosteric pan‐AKT inhibitor that inhibits both the active and inactive forms of AKT1, AKT2, and AKT3 with biochemical IC50 values of 5.0, 4.5, and 16 nM, respectively[5]. Miransertib reduced phosphorylation of AKT and downstream targets of AKT in a concentration‐dependent manner. It showed strong affinity for unphosphorylated full-length AKT1 and potently inhibited the phosphorylated form of full-length AKT isoforms. Miransertib demonstrated high enzymatic potency against AKT1, AKT2, and AKT3, as well as potent cellular inhibition of AKT activation and the phosphorylation of the downstream target PRAS40, and also served as a potent inhibitor of the AKT1-E17K mutant protein inhibited tumor growth in a human xenograft mouse model of endometrial adenocarcinoma[6]. Studies using neutrophils and platelets isolated from sickle cell disease patients revealed that treatment with 50 – 500 nM Miransertib significantly blocks αMβ2 integrin function in neutrophils and reduces P-selectin exposure and glycoprotein Ib/IX/V-mediated agglutination in platelets[7]. Treatment with Miransertib at a dose of 15 mg/kg/day for 7 days every other week can significantly inhibit the tumor growth of HCC[8].
作用机制 Miransertib binds to the allosteric pocket formed by the kinase and PH domains. The aminopyrimidine group of the core moiety forms a bidentate hydrogen bonding interaction with the main chain atoms of loop of β4-strand and αC-helix. The phenylcyclobutylamine side chain associates with the conserved YRD motif of kinase domain by polar and nonpolar interactions[5].

Miransertib HCl 动物研究

Dose Mice: 50 mg/kg - 100 mg/kg[3] (p.o.); 5 mg/kg[4] (i.v.)
Administration p.o., i.v.
Pharmacokinetics
Animal Rats[4] Monkeys[4]
Dose 5 mg/kg 10 mg/kg
Administration p.o. p.o.
F 0.62 0.49
AUCinf 5496 h·ng/ml 2960 h·ng/ml
T1/2 17 h 7 h
Tmax 8.0 h 4.3 h
Cmax 198 ng/ml 258 ng/ml

Miransertib HCl 参考文献

[1]Kim K, Li J, et al. ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease. Haematologica. 2017 Feb;102(2):246-259.

[2]Yu Y, Savage RE, et al. Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. PLoS One. 2015 Oct 15;10(10):e0140479.

[3]Yu Y, Hall T, et al. In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor. Anticancer Drugs. 2017 Jun;28(5):503-513.

[4]Lapierre JM, Eathiraj S, et al. Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor. J Med Chem. 2016 Jul 14;59(13):6455-69.

[5]Leoni C, Gullo G, Resta N, Fagotti A, Onesimo R, Schwartz B, Kazakin J, Abbadessa G, Crown J, Collins CD, Ranieri C, Scambia G, Zampino G. First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma. Am J Med Genet A. 2019 Jul;179(7):1319-1324.

[6]Lapierre JM, Eathiraj S, Vensel D, Liu Y, Bull CO, Cornell-Kennon S, Iimura S, Kelleher EW, Kizer DE, Koerner S, Makhija S, Matsuda A, Moussa M, Namdev N, Savage RE, Szwaya J, Volckova E, Westlund N, Wu H, Schwartz B. Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor. J Med Chem. 2016 Jul 14;59(13):6455-69.

[7]Kim K, Li J, Barazia A, Tseng A, Youn SW, Abbadessa G, Yu Y, Schwartz B, Andrews RK, Gordeuk VR, Cho J. ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease. Haematologica. 2017 Feb;102(2):246-259.

[8]Roth GS, Macek Jilkova Z, Zeybek Kuyucu A, Kurma K, Ahmad Pour ST, Abbadessa G, Yu Y, Busser B, Marche PN, Leroy V, Decaens T. Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma. Mol Cancer Ther. 2017 Oct;16(10):2157-2165.

Miransertib HCl 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.13mL

0.43mL

0.21mL

10.66mL

2.13mL

1.07mL

21.32mL

4.26mL

2.13mL

Miransertib HCl 技术信息

CAS号1313883-00-9
分子式C27H25ClN6
分子量 468.98
SMILES Code NC1=NC=CC=C1C2=NC3=CC=C(C4=CC=CC=C4)N=C3N2C5=CC=C(C6(N)CCC6)C=C5.[H]Cl
MDL No. MFCD31536778
别名
运输蓝冰
InChI Key DRHSWSSVIKDJME-UHFFFAOYSA-N
Pubchem ID 67305743
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Inert atmosphere, store in freezer, under -20°C

溶解方案

DMSO: 50 mg/mL(106.61 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案 一
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。